LearnGlossaryMarketStocksSuperinvestorsSign in

IONS

Ionis Pharmaceuticals, Inc.

Healthcare · $7.4B market cap

Verdict

We can't put a fair value on IONS right now. It has lost money in each of its last 3 years, and our valuation needs recent profits to project from.

Business quality

1 of 5 clear the 10% bar. What are the Big Five?

Earnings per share growth6.4% a year✗
Equity per share growth6.5% a year✗
Sales growth16.8% a year✓
Free cash flow growth8.2% a year✗
Return on invested capital-14.3%✗

Follow IONS

Track it on your watchlist and see the full analysis. Free.

Create a free account

Superinvestors

1 of the investors we track holds IONS. Who we track

Tweedy Browne

Tweedy Browne · as of Q2 2026

$180.8M

2,280,311 shares

Insider activity

Since Aug 31, 2026: no open-market purchases and 4 other filings (stock awards, tax withholding and similar). Why purchases matter

Other filings

Birchler Brian

EVP, Corp and Development Ops · 2026-08-31

J-Other

$3K

Monia Brett P

Chief Executive Officer · 2026-08-31

J-Other

$5K

O'NEIL PATRICK R.

EVP CLO & General Counsel · 2026-08-31

J-Other

$3K

BENNETT C FRANK

EVP, Chief Scientific Officer · 2026-08-31

J-Other

$6K

About Ionis Pharmaceuticals, Inc.

Founded in 1989 and headquartered in Carlsbad, California, Ionis Pharmaceuticals, Inc. is a biopharmaceutical company specializing in the discovery and development of RNA-targeted therapies within the United States. Its commercial portfolio includes three key medications: SPINRAZA, prescribed for spinal muscular atrophy (SMA) in both children and adults; TEGSEDI, an injectable treatment targeting polyneuropathy…

Biotechnology

Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works